in this issue

doi:10.1093/annonc/mdm574

Annals of Oncology 2008 19(1):1; doi:10.1093/annonc/mdm574

This Article

	Full Text
	FREE Full Text (PDF)
	E-letters: Submit a response
	Alert me when this article is cited
	Alert me when E-letters are posted
	Alert me if a correction is posted

Services

	Email this article to a friend
	Related articles in Ann Oncol
	Similar articles in this journal
	Alert me to new issues of the journal
	Add to My Personal Archive
	Download to citation manager
	Request Permissions
	Disclaimer

Google Scholar

	Search for Related Content

Social Bookmarking

	What's this?

© 2007 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.

Breast cancer screening for Hodgkin's lymphoma survivors

Breast cancer remains the most common second malignancy amongfemale survivors of Hodgkin's lymphoma, particularly in thosetreated at young ages with supradiaphragmatic radiation therapy.Cumulative risk increases with radiation dose, time from treatment,and age at end of follow up, with the increased rate of secondarybreast cancer emerging following a latency of 10 years and persistingbeyond 25 years of follow up. Consequently, many of these womenare at . . . [Full Text of this Article]

   Radiation dermatitis and acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for SCCHN

   CNS involvement in mantle cell lymphoma

   Familial cancer

   Quote

Add to CiteULike CiteULike    Add to Connotea Connotea    Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma: L. Lee, M. Pintilie, D. C. Hodgson, P. E. Goss, and M. Crump
Ann Oncol 2008 19: 62-67. [Abstract] [FREE Full Text]
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck: J. Bernier, J Bonner, J. B. Vermorken, R.-J. Bensadoun, R. Dummer, J. Giralt, G. Kornek, A. Hartley, R. Mesia, C. Robert, S. Segaert, and K. K. Ang
Ann Oncol 2008 19: 142-149. [Abstract] [FREE Full Text]
Central nervous system involvement in mantle cell lymphoma: A. Ferrer, F. Bosch, N. Villamor, M. Rozman, F. Graus, G. Gutiérrez, S. Mercadal, E. Campo, C. Rozman, A. López-Guillermo, and E. Montserrat
Ann Oncol 2008 19: 135-141. [Abstract] [FREE Full Text]
How common is familial cancer?: K. Hemminki, J. Sundquist, and J. L. Bermejo
Ann Oncol 2008 19: 163-167. [Abstract] [FREE Full Text]

This article has been cited by other articles:

G. Colloca, F. Checcaglini, and A. Venturino
About sorafenib in castration-resistant prostate cancer
Ann. Onc., October 1, 2008; 19(10): 1812 - 1813.
[Full Text] [PDF]